Barclays PLC increased its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,438 shares of the biotechnology company’s stock after purchasing an additional 20,478 shares during the quarter. Barclays PLC owned 0.13% of Enanta Pharmaceuticals worth $285,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $35,000. US Bancorp DE boosted its stake in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares during the last quarter. Quest Partners LLC boosted its stake in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at approximately $122,000. Finally, Valence8 US LP purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at approximately $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts have recently commented on the company. HC Wainwright reduced their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Robert W. Baird reduced their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $17.25.
Enanta Pharmaceuticals Price Performance
Shares of NASDAQ ENTA opened at $5.58 on Monday. Enanta Pharmaceuticals, Inc. has a 1-year low of $5.30 and a 1-year high of $17.80. The business’s fifty day moving average price is $8.47 and its two-hundred day moving average price is $11.23. The firm has a market capitalization of $118.26 million, a PE ratio of -1.02 and a beta of 0.56.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last issued its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Enanta Pharmaceuticals’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same period last year, the business posted ($1.33) earnings per share. Equities research analysts expect that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current fiscal year.
Insider Activity
In other news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.64% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Featured Stories
- Five stocks we like better than Enanta Pharmaceuticals
- There Are Different Types of Stock To Invest In
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- Investing In Automotive Stocks
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- How Can Investors Benefit From After-Hours Trading
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.